Is Agilent Technologies, Inc. (A) A Good Stock To Buy Now?
Is A a good stock to buy? We came across a bullish thesis on Agilent Technologies, Inc. on Quality At A Fair Price’s Substack. In this article, we will summarize the bulls’ thesis on A.
Agilent Technologies Inc. (A)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Cantillon Capital Management William Von Mueffling | 2,745,829 | $312,969,590 | -12% | 2.08% |
| 2. | Leucadia National Ian Cumming And Joseph Steinberg | 138,826 | $15,823,387 | +15% | 0.11% |
| 3. | Lee Munder Capital Group Lee Munder | 93,891 | $10,701,696 | +8% | 0.64% |
| 4. | Greenhaven Associates Edgar Wachenheim | 10,700 | $1,219,586 | 0.02% | |
| 5. | Arjuna Capital Farnum Brown And Adam Seitchik | 10,015 | $1,141,510 | +2% | 0.29% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.00 | 0 | $0.00 | 24,219 | 2023-09-28 | Filing | |
| $111.09 | 3 | $287.72 | 24,222 | 2023-09-28 | Filing | |
| $37.08 | 600 | $22,248.00 | 46,823 | 2012-08-28 | Filing | |
| $37.28 | 1,155 | $43,058.40 | 46,223 | 2012-08-16 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $149.81 | 2,600 | $389,511.20 | 4,973 | 2025-12-01 | Filing | |
| $154.99 | 3,000 | $464,955.90 | 31,846 | 2025-11-26 | Filing | |
| $143.24 | 911 | $130,491.64 | 32,058 | 2025-11-18 | Filing | |
| $150.00 | 12,490 | $1,873,500.00 | 33,448 | 2025-11-12 | Filing | |
| $124.88 | 2,000 | $249,760.00 | 33,448 | 2025-09-02 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 18,381,030 | $2,095,069,800 | 0.05% | |
| 2. | 14,352,682 | $1,635,918,694 | 0.09% | |
| 3. | 5,984,118 | $682,069,769 | 0.23% | |
| 4. | 3,497,319 | $398,608,928 | 0.42% | |
| 5. | 2,793,604 | $318,414,971 | 0.06% |
News See All
10 Best Diagnostics and Research Stocks to Buy According to Analysts
The diagnostics and research sector holds a crucial position in the healthcare ecosystem, thus attracting investor interest.
Emerald Growth Equity Strategy Sold Agilent (A) Due to Compression in the Margin of Safety
Emerald Wealth Partners, an independent asset and wealth management firm based in Zurich, released its Q4 2025 investor letter for the “Growth Equity Strategy.” A copy of the letter is available to...
Jim Cramer Expressed His Thoughts on 14 Stocks: Arm, Costco, and More
I'm going to give you four things that need to happen no matter what before this situation can go back to normal, and remember what normal means.
Agilent Technologies, Inc. (A) Price Target Cut to $155 at Baird
On February 26, Baird lowered the firm’s price target on Agilent Technologies, Inc.
10 Stocks That Could Skyrocket in 2026
Investing in stocks with high upside potential is ultimately about capturing asymmetric reward by allocating capital to opportunities where the prospective gains meaningfully outweigh the risks.
Agilent (A) Gets Lower Goldman Sachs Target Despite Long-Term Growth Confidence
On February 27, Goldman Sachs lowered its price recommendation on Agilent Technologies, Inc. (NYSE:A) to $150 from $170. The firm reiterated a Buy rating on the shares.
13 Best Income Stocks With Highest Upside Potential
According to a recent report by BlackRock, many retirees could be entering 2026 at a meaningful turning point.
Agilent Technologies, Inc. (NYSE:A) Q1 2026 Earnings Call Transcript
Operator: Ladies and gentlemen, thank you for joining us, and welcome to the Q1 2026 Agilent Technologies Inc. Earnings Conference Call.
Agilent Technologies, Inc. (A) Sparks Confidence With Latest Approvals
On February 12, Agilent Technologies, Inc. (NYSE:A) announced that its PD-L1 IHC 22C3 pharmDx, Code SK006, had been approved by the U.S. FDA.
Hedge Fund Resource Center